mrd
No description yet: the sentence for this tag has not been written. 5 records carry it: 4 people, 1 roadmap.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
C. Ola Landgren Chief of Myeloma and Director of the Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami · Sylvester Comprehensive Cancer Center, University of Miami Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant. | Multiple myeloma | none | myeloma, precursor | ||
ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment Blood carries fragments of tumour DNA. This roadmap follows the tests that read them, from the first sighting in 1948 to blood tests that now choose a drug, spare chemotherapy, or screen for many cancers at once, and it lists the readouts to watch next. | none | none | ctdna, liquid-biopsy, mced | ||
Nicola Gökbuget Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt · University Cancer Center Frankfurt (UCT) Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL. | Acute lymphoblastic leukaemia | none | all, cooperative-group | ||
Peter Hillmen Emeritus Professor of Experimental Haematology, University of Leeds · Leeds Cancer Centre, St James's University Hospital Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL. | Chronic lymphocytic leukaemia | none | cll, uk | ||
Viktor A. Adalsteinsson Director, Gerstner Center for Cancer Diagnostics, Broad Institute of MIT and Harvard · Broad Institute of MIT and Harvard Engineer who showed low-pass sequencing of blood can replace tumour biopsies and built ultra-sensitive MRD tests. | none | none | ctdna, diagnostics |